ERBB2 and breast cancer: Based on these conflicting results, no clear conclusions can be drawn at present time on both the prognostic value of HER2-low expression and the distinct biologic/clinical entity of HER2-low BC, and this is likely due to differences in the studied patient population, the HR status, the study design/endpoint, and/or follow-up duration.